Content of M2 macrophages in the atherosclerotic lesions but also within the liver calls for
Content of M2 macrophages in the atherosclerotic lesions but also within the liver calls for additional investigations. In turn, CSAD is an enzyme participating in taurine biosynthesis, which converts cysteine sulfinic acid to hypotaurine and CO2 . Our proteomics outcomes showed increased expression of CSAD in the liver of DIZE-treated apoE-/- mice, which was moreover confirmed by Western blot. Regularly, we also observed elevated taurine concentration within the liver of apoE-/- mice after DIZE administration. Taurine is one of the most abundant amino acids in mammals and basic regulator of biological and physiological processes. It has been shown that taurine could prevent atherogenesis in mice and rabbits by influencing osmoregulation, oxidation, and inflammation [39] as well as could attenuate hepatic steatosis in mice on an HFD by way of the inhibition of oxidative strain [40]. Interestingly, taurine has been also reported to modulate the phenotype of macrophages towards increasing M2 macrophages in adipose tissues, which was measured by elevated gene expression of M2 markers: Ym1, Arg1, and MGL1 [41]. Therefore, enhanced biosynthesis and concentration of taurine inside the liver of apoE-/- mice treated with DIZE may be presumably one of the beneficial mechanisms of DIZE action inside the reduction in hepatic steatosis and stabilization of atherosclerotic plaques. In our setting, the use of DIZE didn’t modify the response on the mesenteric arteries to phenylephrine and the NO donor (DEA-NO) but enhanced the endothelial-dependent relaxation induced by acetylcholine. The mechanism of such effect could depend on a rise in endothelial eNOS-derived NO release and/or improvement of NO bioavailability. Interestingly, DIZE has recently been shown to boost NO production in the mesenteric artery of SHR-treated rats, but the mechanism of this action has not been completely characterized [42]. Intriguingly, not too long ago NO secretion-enhancing effect of taurine has been described [43]. Many doable mechanisms of such action of taurine happen to be proposed, i.e., escalating eNOS expression, eNOS phosphorylation on Ser1177, NO bioavailability, the level of antioxidative defense, along with the influence on L-arginine/NOS inhibitor asymmetric dimethylarginine (ADMA) ratio, however, regardless of whether and which of them may be involved in the action of DIZE in our experimental model calls for further study. Our analysis has numerous strengths: we investigated a compound having a low, wellestablished toxicity that is definitely effectively suited to repurposing and new use. We also pointed out new, exciting mechanisms from the drug’s action that might be accountable for the stabilization of atherosclerotic plaque along with the reduction in fatty liver. It can be tempting to speculate that ACE2 activator, DIZE, offers potentially a novel therapeutic approachInt. J. Mol. Sci. 2021, 22,11 ofto the treatment/prevention of atherosclerosis and fatty liver ailments by influencing macrophages polarization and taurine biosynthesis. Nonetheless, the precise understanding of mechanisms in the CXCR1 Formulation advantageous actions of DIZE demand additional studies. Nonetheless, our study has numerous limitations. DIZE is primarily recognized as an antitrypanosomal drug and ACE2 activator, BChE custom synthesis however it also elicits other pharmacological properties. It could inhibit acid-sensitive ion channels (ASIC1a , ASIC1b , ASIC2a , and ASIC3 ), which play a function in the perception of pH changes during extracellular tissue acidosis [44]. Also, some studies sh.